Preeclampsia: A "Nephrocentric" View

Advances in Chronic Kidney Disease

Volumn 20, Issue 3, 2013, Pages 280-286

  August, Phyllis ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

Hypertension in pregnancy; Preeclampsia; Proteinuria in pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METHYLDOPA; NIFEDIPINE;

ACUTE KIDNEY FAILURE; ANTICOAGULATION; BRAIN DYSFUNCTION; DELIVERY; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FETUS MORTALITY; GLOMERULUS FILTRATION RATE; HUMAN; LIVER DYSFUNCTION; MATERNAL HYPERTENSION; MICROANGIOPATHY; MORBIDITY; NEPHROLOGIST; PATHOGENESIS; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ACUTE KIDNEY INJURY; ECLAMPSIA; FEMALE; GLOMERULAR FILTRATION RATE; HELLP SYNDROME; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; KIDNEY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEINURIA; THROMBOTIC MICROANGIOPATHIES;

EID: 84876875415     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.01.013     Document Type: Review

References (56)

1. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376(9741):631-644.
2. Roberts J.M., Lain K.Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002, 23(5):359-372.
3. Martin J.N., Thigpen B.D., Moore R.C., Rose C.H., Cushman J., May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005, 105(2):246-254.
4. Melchiorre K., Sutherland G., Sharma R., Nanni M., Thilaganathan B. Mid-gestational maternal cardiovascular profile in preterm and term pre-eclampsia: a prospective study. BJOG 2013, 120(4):496-504.
5. August P., Lenz T., Ales K.L., et al. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: deviations related to the development of superimposed preeclampsia. Am J Obstet Gynecol 1990, 163(5 Pt 1):1612-1621.
6. Conrad K.P. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol 2011, 31(1):15-32.
7. Salas S.P., Marshall G., Gutierrez B.L., Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006, 47(2):203-208.
8. George E.M., Granger J.P. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011, 24(9):964-969.
9. Walsh S.W. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004, 70(2):223-232.
10. Wallukat G., Homuth V., Fischer T., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103(7):945-952.
11. Schobel H.P., Fischer T., Heuszer K., Geiger H., Schmieder R.E. Preeclampsia-a state of sympathetic overactivity. N Engl J Med 1996, 335(2):1480-1485.
12. Bond A.L., August P., Druzin M.L., Atlas S.A., Sealey J.E., Laragh J.H. Atrial natriuretic factor in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989, 160(5 Pt 1):1112-1116.
13. Pedersen E.B., Christensen N.J., Christensen P., et al. Preeclampsia-a state of prostaglandin deficiency? Urinary prostaglandin excretion, the renin-aldosterone system, and circulating catecholamines in preeclampsia. Hypertension 1983, 5(1):105-111.
14. Buhl K.B., Friis U.G., Svenningsen P., et al. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension 2012, 60(5):1346-1351.
15. Raymond D., Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 2011, 66(8):497-506.
16. Ward K., Hata A., Jeunemaitre X., et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 1993, 4(1):59-61.
17. Hillermann R., Carelse K., Gebhardt G.S. The glu298asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. J Hum Genet 2005, 50(8):415-419.
18. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989, 161(5):1200-1204.
19. Roberts J.M., Redman C.W. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993, 341(8858):1447-1451.
20. Kupferminc M.J., Peaceman A.M., Wigton T.R., Rehnberg K.A., Socol M.L. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994, 170(6):1752-1757. discussion 1757-1759.
21. LaMarca B., Speed J., Fournier L., et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension 2008, 52(6):1161-1167.
22. Roberts J.M., Hubel C.A. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 1999, 354(9181):788-789.
23. Knight M., Redman C.W., Linton E.A., Sargent I.L. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998, 105(6):632-640.
24. Anim-Nyame N., Sooranna S.R., Steer P.J., Johnson M.R. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia. Hum Reprod 2000, 15(9):2033-2036.
25. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
26. Maynard S.E., Karumanchi S.A. Angiogenic factors and preeclampsia. Semin Nephrol 2011, 31(1):33-46.
27. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90(22):10705-10709.
28. de Jesus-Gonzalez N., Robinson E., Moslehi J., Humphreys B.D. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012, 60(3):607-615.
29. Cross S.N., Ratner E., Rutherford T.J., Schwartz P.E., Norwitz E.R. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012, 5(1):2-8.
30. Kappers M.H., de Beer V.J., Zhou Z., et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012, 59(1):151-157.
31. Pettit F., Brown M.A. The management of pre-eclampsia: what we think we know. Eur J Obstet Gynecol Reprod Biol 2012, 160(1):6-12.
32. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sflt-1) induces proteinuria. J Biol Chem 2003, 278(150):12605-12608.
33. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-a expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111(5):707-716.
34. Thadhani R., Kisner T., Hagmann H., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011, 124(8):940-950.
35. Garovic V.D., Wagner S.J., Turner S.T., et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007, 196(4):320.e321-320.e327.
36. Garovic V.D., Wagner S.J., Petrovic L.M., et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transpl 2007, 22(4):1136-1143.
37. Wang Y., Zhao S., Loyd S., Groome L.J. Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia. Am J Physiol Renal Physiol 2012, 302(9):F1084-F1089.
38. Son G.H., Kwon J.Y., Lee S., et al. Comparison of serum and urinary nephrin levels between normal pregnancies and severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2013, 166(2):139-144.
39. Lafayette R.A., Druzin M., Sibley R., et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 1998, 54(4):1240-1249.
40. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 1981, 88(1):1-9.
41. Cornelis T., Odutayo A., Keunen J., Hladunewich M. The kidney in normal pregnancy and preeclampsia. Semin Nephrol 2011, 31(1):4-14.
42. Moran P., Baylis P.H., Lindheimer M.D., Davison J.M. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003, 14(3):648-652.
43. Fakhouri F., Vercel C., Fremeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012, 7(12):2100-2106.
44. Gul A., Aslan H., Cebeci A., Polat I., Ulusoy S., Ceylan Y. Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure. Ren Fail 2004, 26(5):557-562.
45. Brown M.A., Holt J.L., Mangos G.J., Murray N., Curtis J., Homer C. Microscopic hematuria in pregnancy: relevance to pregnancy outcome. Am J Kidney Dis 2005, 45(4):667-673.
46. Leduc L., Lederer E., Lee W., Cotton D.B. Urinary sediment changes in severe preeclampsia. Obstet Gynecol 1991, 77(2):186-189.
47. Fakhouri F., Jablonski M., Lepercq J., et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008, 112(12):4542-4545.
48. Yang Z., Zhao Y., Bennett M.J., Strauss A.W., Ibdah J.A. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002, 187(3):715-720.
49. Treem W.R., Rinaldo P., Hale D.E., et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Hepatology 1994, 19(2):339-345.
50. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007, 369(9575):1791-1798.
51. Lindheimer M.D., Sibai B.M. Antioxidant supplementation in pre-eclampsia. Lancet 2006, 367(9517):1119-1120.
52. de Vries J.I., van Pampus M.G., Hague W.M., Bezemer P.D., Joosten J.H. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012, 10(1):64-72.
53. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334(8):494-500.
54. Wagner S.J., Acquah L.A., Lindell E.P., et al. Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control. Mayo Clin Proc 2011, 86(9):851-856.
55. Podymow T., August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010, 29(3):294-300.
56. Kuklina E.V., Tong X., Bansil P., George M.G., Callaghan W.M. Trends in pregnancy hospitalizations that included a stroke in the united states from 1994 to 2007: reasons for concern?. Stroke 2011, 42(9):2564-2570.